Genmab (GMAB)
(Delayed Data from NSDQ)
$27.69 USD
-0.88 (-3.08%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $27.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GMAB 27.69 -0.88(-3.08%)
Will GMAB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 17th
GMAB or TECH: Which Is the Better Value Stock Right Now?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
Other News for GMAB
Decoding 9 Analyst Evaluations For Genmab
Genmab’s TIVDAK Wins Full FDA Approval
Pfizer, Genmab cervical cancer therapy wins full FDA approval
Buy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline Valuation
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer